Bionano Genomics Inc. [NASDAQ: BNGO] loss -8.36% or -0.31 points to close at $3.40 with a heavy trading volume of 13923313 shares. The company report on November 29, 2021 that Bionano Genomics Appoints Dr. Keith Gligorich, Seasoned Leader in CLIA-Certified CAP-Accredited Lab Operations, as VP Operations for Bionano Laboratories.
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of the leading software for genomic data visualization, interpretation and reporting, announced that it has appointed Keith Gligorich, PhD, MB(ASCP)cm to the role of VP Operations for Bionano Laboratories. Keith was most recently with Guarant Health where he led the build-out of Guardant’s CLIA-certified, CAP-accredited laboratory for blood-based early cancer detection testing. He has over a decade of experience in molecular diagnostic test development and laboratory operations. Prior to joining Guardant Health, Keith held leadership roles at ARUP Laboratories, Navican Genomics and Cradle Genomics. Keith holds a PhD in organic chemistry from the University of Utah.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
“We are delighted to have Keith on board. We believe he is an expert when it comes to CLIA labs and lab developed tests (LDTs) operating at the forefront of science and technology,” commented Dr. Alka Chaubey, chief medical officer of Bionano. “We look forward to Keith leading the planned expansion of our offering to include services and LDTs under CLIA-certification and CAP-accreditation within Bionano Laboratories.”.
It opened the trading session at $3.68, the shares rose to $3.725 and dropped to $3.34, the range by which the price of stock traded the whole day. The daily chart for BNGO points out that the company has recorded -59.52% loss over the past six months. However, it is still -593.88% lower than its most recent low trading price.
If we look at the average trading volume of 8.45M shares, BNGO reached to a volume of 13923313 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Bionano Genomics Inc. [BNGO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNGO shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNGO stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 16, 2021. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 24, 2020, representing the official price target for Bionano Genomics Inc. stock. Previously, the target price had yet another raise to $1.50, while Oppenheimer analysts kept a Outperform rating on BNGO stock.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.31, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 62.77. The Price to Book ratio for the last quarter was 2.79, with the Price to Cash per share for the same quarter was set at 1.12.
Trading performance analysis for BNGO stock
Bionano Genomics Inc. [BNGO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.00. With this latest performance, BNGO shares dropped by -44.44% in over the last four-week period, additionally sinking by -59.52% over the last 6 months – not to mention a rise of 584.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 18.71, with the RSI for the last a single of trading hit 10.51, and the three-weeks RSI is set at 25.16 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 4.99, while it was recorded at 3.73 for the last single week of trading, and 6.29 for the last 200 days.
Bionano Genomics Inc. [BNGO]: A deeper dive into fundamental analysis
Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 18.80 and a Current Ratio set at 19.30.
Bionano Genomics Inc. [BNGO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Bionano Genomics Inc. posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.05/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -60.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNGO.
An analysis of insider ownership at Bionano Genomics Inc. [BNGO]
There are presently around $246 million, or 25.30% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: BLACKROCK INC. with ownership of 18,160,323, which is approximately -0.942% of the company’s market cap and around 1.90% of the total institutional ownership; VANGUARD GROUP INC, holding 15,053,272 shares of the stock with an approximate value of $51.18 million in BNGO stocks shares; and STATE STREET CORP, currently with $25.58 million in BNGO stock with ownership of nearly 0.09% of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 76 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 7,475,305 shares. Additionally, 74 investors decreased positions by around 9,674,085 shares, while 33 investors held positions by with 55,282,257 shares. The mentioned changes placed institutional holdings at 72,431,647 shares, according to the latest SEC report filing. BNGO stock had 22 new institutional investments in for a total of 1,048,245 shares, while 26 institutional investors sold positions of 1,355,581 shares during the same period.